300639.SZ SHZ
Guangdong Hybribio Biotech Co.,Ltd.
1W: +2.4%
1M: +6.8%
3M: +21.8%
YTD: -13.8%
1Y: -6.1%
3Y: -42.1%
5Y: -50.8%
¥6.32 ($0.94)
+0.12 (+1.94%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$79M
-75.4% ▼
5Y CAGR: -6.9%
Capital Expenditures
$148M
+61.5% ▲
5Y CAGR: -5.5%
Free Cash Flow
-$70M
-5.8% ▼
Dividends Paid
$44M
+70.5% ▲
Buybacks
$65M
-30.2% ▼
Net Change in Cash
-$99M
+61.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $395M | $885M | $1.8B | $140M | -$950M |
| Depreciation & Amort. | $50M | $87M | $179M | $192M | $170M |
| Stock-Based Comp. | $789K | $7M | $6M | $0 | $0 |
| Change in Working Capital | -$163M | -$383M | -$1.4B | $135M | $78M |
| Other Non-Cash Items | $19M | $8M | $762M | -$148M | $782M |
| Operating Cash Flow | $311M | $631M | $1.3B | $320M | $79M |
| — Investing Activities — | |||||
| Capital Expenditures | -$287M | -$641M | -$734M | -$385M | -$148M |
| Acquisitions (Net) | $294M | $3M | $14M | $0 | $0 |
| Investment Purchases | -$2.2B | -$2.6B | -$2.5B | -$1.0B | -$657M |
| Investment Sales | $1.2B | $2.8B | $2.7B | $1.1B | $694M |
| Other Investing | -$287M | $4M | $0 | $18M | $399K |
| Investing Cash Flow | -$1.2B | -$503M | -$605M | -$293M | -$110M |
| — Financing Activities — | |||||
| Net Debt Issuance | $75M | $76M | -$53M | -$68M | $44M |
| Stock Repurchased | -$50M | -$50M | -$50M | -$50M | -$65M |
| Dividends Paid | -$42M | -$70M | -$102M | -$151M | -$44M |
| Other Financing | $1.0B | $12M | -$2M | -$25M | -$9M |
| Financing Cash Flow | $1.0B | $8M | -$219M | -$294M | -$75M |
| Net Change in Cash | $134M | $131M | $498M | -$259M | -$99M |
| Cash End of Period | $391M | $522M | $1.0B | $761M | $662M |
| Free Cash Flow | $24M | -$10M | $575M | -$66M | -$70M |